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Abstract
Background: Heterogeneity of endothelial cells (ECs) is a hallmark of the vascular system which may impact the
development and management of vascular disorders. Despite the tremendous progress in differentiation of human
embryonic stem cells (hESCs) towards endothelial lineage, differentiation into arterial and venous endothelial
phenotypes remains elusive. Additionally, current differentiation strategies are hampered by inefficiency, lack of
reproducibility, and use of animal-derived products.
Methods: To direct the differentiation of hESCs to endothelial subtypes, H1- and H9-hESCs were seeded on human
plasma fibronectin and differentiated under chemically defined conditions by sequential modulation of glycogen
synthase kinase-3 (GSK-3), basic fibroblast growth factor (bFGF), bone morphogenetic protein 4 (BMP4) and vascular
endothelial growth factor (VEGF) signaling pathways for 5 days. Following the initial differentiation, the endothelial
progenitor cells (CD34+CD31+ cells) were sorted and terminally differentiated under serum-free conditions to
arterial and venous ECs. The transcriptome and secretome profiles of the two distinct populations of hESC-derived
arterial and venous ECs were characterized. Furthermore, the safety and functionality of these cells upon in vivo
transplantation were characterized.
Results: Sequential modulation of hESCs with GSK-3 inhibitor, bFGF, BMP4 and VEGF resulted in stages reminiscent
of primitive streak, early mesoderm/lateral plate mesoderm, and endothelial progenitors under feeder- and serum-
free conditions. Furthermore, these endothelial progenitors demonstrated differentiation potential to almost pure
populations of arterial and venous endothelial phenotypes under serum-free conditions. Specifically, the endothelial
progenitors differentiated to venous ECs in the absence of VEGF, and to arterial phenotype under low
concentrations of VEGF. Additionally, these hESC-derived arterial and venous ECs showed distinct molecular and
functional profiles in vitro. Furthermore, these hESC-derived arterial and venous ECs were nontumorigenic and were
functional in terms of forming perfused microvascular channels upon subcutaneous implantation in the mouse.
Conclusions: We report a simple, rapid, and efficient protocol for directed differentiation of hESCs into endothelial
progenitor cells capable of differentiation to arterial and venous ECs under feeder-free and serum-free conditions.
This could offer a human platform to study arterial–venous specification for various applications related to drug
discovery, disease modeling and regenerative medicine in the future.
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Background
The vascular system consists of a complex network of
arteries and veins that are lined by a monolayer of cells
called endothelial cells (ECs). Although the arterial and
venous ECs share certain common molecular signatures
such as the expression of pan-endothelial markers
(CD31, vascular endothelial cadherin (VE-CAD), and
von Willebrand factor (vWF)), they do possess certain
distinct molecular profiles [1, 2]. Such molecular distinc-
tion seems to occur quite early in the development even
before the onset of blood flow and involves the interplay
of various signaling pathways such as sonic hedgehog
(Shh), vascular endothelial growth factor (VEGF), Notch,
cyclic adenosine monophosphate (cAMP), and chicken
ovalbumin upstream promoter-transcription factor II
(COUP-TFII) [3]. Arterial ECs are characterized by ex-
pression of Ephrin-B2, Delta-like 4 (DLL4), Hey-1, Hey-2,
neuropilin-1 (NRP1), Notch-1, Notch-4, chemokine
receptor-4 (CXCR4), Jag-1 and Jag-2, while the venous
ECs express Eph-B4, Lefty-1, Lefty-2, neuropilin-2 (NRP2)
and COUP-TFII [1]. Due to lack of access to human em-
bryos, most of our understanding regarding the molecular
mechanisms of arterial–venous specification is based on
studies in zebrafish, Xenopus and mouse embryos, and a
few studies using stem/progenitor cells. Additionally, gen-
etic, molecular and functional studies of human ECs are
limited by the availability of umbilical, neonatal or adult
sources.
Recent advances in stem cell biology have provided
a surrogate tool to study human development through
pluripotent stem cells (PSCs) that include human em-
bryonic stem cells (hESCs) and induced pluripotent
stem cells (iPSCs) [4]. Differentiation of PSCs into
ECs is of growing interest as it provides an opportun-
ity to study vascular development in both physio-
logical and diseased states. Secondly, the PSC-derived
ECs could serve as a surrogate human vascular model
to study various cellular and molecular aspects of
angiogenesis [5]. Furthermore, these cells also provide
access to abundant populations of cells for the
pharmaceutical industry to screen and develop novel
cardiovascular compounds [6, 7]. Finally, in the long
term, these cells have the potential for cellular therapy
to repair ischemic tissues and develop tissue-
engineered vascular grafts.
We and others have reported differentiation of hPSCs
towards mature and functional ECs [8–17]. Briefly, these
protocols involve: (1) embryoid body-based differenti-
ation, (2) co-culture of PSCs over murine stromal cells,
and (3) monolayer differentiation over extracellular
matrix (ECM) proteins like Matrigel and collagen IV
[5, 18]. Despite the tremendous progress in differenti-
ation of hESCs towards endothelial lineage, very lim-
ited data are available on how these stem cells could
be coaxed into arterial or venous ECs. Secondly, these
differentiation protocols have limitations such as low
differentiation efficiency and use of xenogeneic (ani-
mal-derived) products such as fetal bovine serum
(FBS), murine feeder cells and/or ECM [5]. Addition-
ally, the undefined nature of serum and other xeno-
geneic components limits the ability to tune the
cellular microenvironment and in turn affects the effi-
ciency and reproducibility of the protocol [16, 19].
Furthermore, these xenogeneic components limit the
clinical translation potential owing to potential risk of
transmission of animal pathogens, and ectopic expres-
sion of immunogenic minor histocompatibility anti-
gens that could lead to xenogeneic rejection [16].
Hence, large-scale production of ECs from hESCs for
various research and clinical applications would re-
quire: (1) efficient induction of hESCs towards endo-
thelial lineage and specifically towards different
arterial and venous ECs, and (2) elimination or reduc-
tion of xenogeneic products.
A reliable approach to generate ECs from hESCs
would be to recapitulate the embryonic vasculogenesis
under defined conditions based on a thorough under-
standing of the key developmental events and signaling
pathways controlling them. In this study, we established
a stepwise differentiation of hESCs to arterial and ven-
ous ECs through stages reminiscent of Brachyury+
primitive streak (PS), VEGFR2+ early mesoderm/lateral
plate mesoderm, CD34+CD31+ (VEGFR2+) endothelial
progenitors and then to arterial (CD31+/NRP1+/DLL4+)
and venous (CD31+/NRP2+/EphB4+) ECs under feeder-
and serum-free conditions. These endothelial pheno-
types displayed differences in transcriptome and secre-
tome profiles, they were nontumorigenic and formed
functional blood vessels that integrated with the host
circulation and maintained their respective phenotypes
in vivo.
Methods
Culture of hESCs under feeder-free and serum-free
conditions
For feeder- and serum-free culture, H1- and H9-hESCs
(WiCell Research Institute, Madison, WI, USA) were
cultured in chemically defined medium (mTeSR™1;
StemCell Technologies) on Matrigel-coated plates
(356230, BD Biosciences) as previously described [20].
Briefly, 70–80 % confluent hESCs were passaged after
treatment with 1 mg/ml dispase (Invitrogen) for 5 mi-
nutes at 37 °C. The hESC colonies were dispersed into
small clumps and re-plated onto Matrigel-coated plates.
The pluripotency status of the hESCs was confirmed
by immunocytochemical expression of OCT4, SSEA3/4,
TRA-1-60, TRA-1-81 and alkaline phosphatase (Additional
file 1: Figure S1).
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Directed differentiation of hESCs under chemically
defined conditions
After incubation with dispase (1 mg/ml; 5 minutes), un-
differentiated hESC colonies of size ~300–500 cells per
colony were gently cut into small squares using a 200 μl
gel loading pipette tip under a stereomicroscope
(Olympus). These cut hESC colonies were gently aspirated
and seeded onto 4 μg/cm2 human plasma fibronectin
(GIBCO)-coated plates (seeding density: ~2 hESC col-
onies/cm2). The pluripotency status of hESCs seeded onto
fibronectin-coated plates for 24 hours was investigated by
real-time reverse-transcriptase polymerase chain reaction
(RT-PCR) and immunocytochemical staining (Additional
file 1: Figure S2). These hESC colonies on fibronectin were
maintained in mTeSR™1 for 24 hours, after which the cells
were gently washed with DMEM:F12 (Invitrogen) and dif-
ferentiated in chemically defined, serum-free, animal
component-free medium [21] (STEMdiff™APEL™; Stem-
Cell Technologies) supplemented with appropriate factors
as depicted in Figs. 1 and 2. To induce hESCs towards PS,
Fig. 1 Time course analysis of expression of genes associated with pluripotency and early differentiation of human embryonic stem cells (hESCs)
in response to inhibition of glycogen synthase kinase-3 (GSK-3). a Schematic representation of differentiation of hESCs with or without the
inhibition of GSK-3 using CHIR99021 (±GSKi). Real-time RT-PCR analysis of markers associated with pluripotency and neuroectoderm (b), primitive
streak (PS)/mesendoderm, epithelial–mesenchymal transition (EMT), anterior PS/endoderm, and mesodermal subsets (c) after differentiation of
hESCs with (grey bars) or without (black bars) GSKi. For all gene expression plots, expression levels were normalized to corresponding β-ACTIN
values and are shown relative to undifferentiated hESCs. The expression levels of SOX2, OCT4, NANOG, PAX6, SOX1 and VEGFR2 were log-normalized
to reveal the amount of downregulation in relation to undifferentiated hESCs. Error bars show standard deviations; n≥ 3. *p < 0.05, **p < 0.01, versus
without GSKi. d Confocal immunofluorescence micrographs show expression of OCT4 and BRACHYURY after differentiation with or without GSKi. Scale
bars = 200 μm. DMSO Dimethyl sulfoxide,
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the hESCs were exposed to glycogen synthase kinase-3
(GSK-3) inhibitor (CHIR99021; 5 μM; Stemgent) for 24
hours as previously reported [17, 22]. After 24-hour ex-
posure of hESCs to CHIR99021, mesodermal induction of
PS was carried out using basic fibroblast growth factor
(bFGF) (50 ng/ml) with or without FGF receptor inhibitor
(PD173074; 0.1 μM), and endodermal differentiation of PS
was induced using Activin-A (50 ng/ml) with or without
Activin and transforming growth factor (TGF)-β signaling
inhibitor SB431542 (10 μM) as illustrated in Additional
file 1 (Figures S3 and S4). Following induction of PS,
mesodermal and endothelial induction was carried out in
the presence of bFGF (50 ng/ml; R&D systems) for 24
hours followed by 72 hours of bone morphogenetic pro-
tein 4 (BMP4; 25 ng/ml; R&D systems) and VEGF
(50 ng/ml; GIBCO) (Fig. 2a).
Differentiation of endothelial progenitors (CD34+CD31+
cells) to endothelial subtypes in feeder-free, serum-free
conditions
After 5 days of differentiation in STEMdiff™APEL™,
CD34+CD31+ cells were isolated by flow cytometry
Fig. 2 Kinetics of transcripts associated with early endothelial induction and pluripotency of human embryonic stem cells (hESCs). a Schematic
representation of differentiation of H1-hESCs towards endothelial progenitors by sequential treatment with CHIR99021 (+GSKi) and basic fibroblast
growth factor (bFGF) for 24 hours each followed by exposure to bone morphogenetic protein 4 (BMP4) and/or vascular endothelial growth factor
(VEGF). b Kinetics of expression of VEGFR2, CD34 and CD31 upon induction with BMP4 (Gi.F.B), VEGF (Gi.F.V) and BMP4 + VEGF (Gi.F.BV) over a
differentiation period of 5 days. c Time course expression kinetics of pluripotency genes (OCT4, SOX2, NANOG) over 5 days of differentiation
among the three differentiation conditions. For gene expression plots in (b) expression levels were normalized to corresponding β-ACTIN values
and are shown relative to undifferentiated hESCs, while for those in (c) the expression levels were log-normalized to reveal the amount of
downregulation in relation to undifferentiated hESCs. Error bars show standard deviations; n ≥ 3. *p < 0.05, **p < 0.01, versus Gi.F.B
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assisted sorting (FACS), and plated onto 2 μg/cm2 hu-
man plasma fibronectin-coated plates (12,000 cells per
cm2) and cultured in endothelial serum-free medium
(ESFM; GIBCO) with media changes every 2–3 days.
Venous differentiation was induced using 10 ng/ml
epidermal growth factor (EGF; R&D Systems), and 20
ng/ml bFGF. For arterial differentiation, the medium
was supplemented with 10 ng/ml EGF, 20 ng/ml
bFGF, and 10 ng/ml VEGF. The endothelial cells were
passaged using accutase (Invitrogen) when 70–80 %
confluent and characterized after 3 to 5 passages.
In vivo studies
All experiments involving handling and manipulation of
animals were approved by the Institutional Animal Care
and Use Committee, National University of Singapore,
and the Institutional Review Board, National University
of Singapore. To assess the angiogenic potential of
hESC-derived arterial and venous ECs, 1 × 106 hESC ar-
terial ECs (Art-ECs) or hESC venous ECs (Ven-ECs)
were suspended in 200 μl of growth factor-reduced
Matrigel and injected subcutaneously in each side of the
dorsal region of 8- to 9-week-old nonobese diabetic
(NOD)/severe combined immunodeficiency (SCID) mice
[NOD.CB17-Prkdcscid/J] (two implants per mouse; three
mice per experimental condition). Matrigel plug without
cells served as control. After 2 weeks, the Matrigel plug
was harvested with the surrounding tissues and proc-
essed for histological analysis.
To assess the safety of hESC-derived ECs, 1 × 106 hESCs,
hESC-Art-ECs, or hESC-Ven-ECs were suspended in 200 μl
of phosphate-buffered saline and injected subcutaneously
in each side of the dorsal region of 6- to 8-week-old
NOD/SCID mice [NOD.CB17-Prkdcscid/J] (two implants
per mouse; three mice per experimental condition). After
4 months or formation of tumor mass ≥1.5 cm in size
(whichever was earlier), the mice were sacrificed and the
tissue around the point of injection was harvested and
processed for histological analysis.
Supplementary methods
For additional methods refer to Additional file 1. Infor-
mation related to list of primers and antibodies used in
the study are presented in Additional file 1.
Results
For all the differentiation studies the H1-hESC line was
used primarily, and the robustness of the protocol veri-
fied using H9-hESCs.
Temporal emergence of primitive streak capable of
commitment to mesoderm and endoderm
In early embryogenesis, mesoderm that gives rise to cells
of the vascular lineage arises through an epithelial–
mesenchymal transition (EMT) of epiblast cells in the
region of PS. For differentiation to PS, we modified our
previously published protocol [17], using plasma fibro-
nectin as substrate and CHIR99021 (5 μM) to inhibit
GSK-3 under chemically defined conditions. During the
induction of PS, we observed a marked downregulation
of the pluripotency gene SOX2 within 24 hours, followed
by OCT4 and NANOG, and the neuroectoderm-
associated genes (PAX6, SOX1) (Fig. 1a and b). In con-
trast to the downregulation of neuroectodermal genes,
the PS-related genes (BRACHYURY, MIXL1) were up-
regulated synchronously along with anterior PS genes
(FOXA2, GSC) and peaked at day 1 of differentiation
(Fig. 1c). Furthermore, the temporal expression of PS-
related genes was accompanied by upregulation of the
gene involved in EMT (SNAI1). The expression of BRA-
CHYURY along with OCT4 after 24 hours of inhibition
of GSK-3 was confirmed by immunofluorescence
(Fig. 1d). Temporal expression of Brachyury accompan-
ied with EMT suggests the emergence of Brachyury+ PS-
like cells at early stages of inhibition of GSK-3 as previ-
ously reported [17, 23–25].
Cells of the PS have the ability to commit to mesoderm
and endodermal progenies depending on the balance be-
tween bFGF, Activin and BMP4 signaling [3, 17, 23, 26].
We next sought to ascertain the differentiation capacity of
PS towards mesoderm and endoderm, as illustrated in
Additional file 1 (Figures S3 and S4). Real-time PCR ana-
lysis revealed that induction with bFGF resulted in modest
upregulation of lateral and paraxial mesodermal tran-
scripts (VEGFR2, PDGFRα, PDGFRβ) accompanied by
downregulation of PS and endoderm-related transcripts
(FOXA2, GSC, CXCR4) (Additional file 1: Figure S3). On
the contrary, treatment of PS with Activin-A resulted in
marked upregulation of endodermal transcripts and
downregulation of PS and mesoderm-related transcripts,
while these findings were abrogated in the presence of
SB431542 (Additional file 1: Figure S4). Collectively, these
observations demonstrate the potential of hESCs differen-
tiated to PS under the influence of GSK-3 inhibition
(for 24 hours) to commit towards mesoderm or endo-
derm depending on the culture milieu provided.
VEGF is essential and sufficient for endothelial
commitment from early mesodermal cells, and BMP4 is
synergistic
Inhibition of GSK-3 followed by bFGF exposure drives
the hESCs towards lateral plate mesoderm as evidenced
by the upregulation of VEGFR2 and downregulation of
PS and endoderm-related genes. We next sought to in-
vestigate the potential of these lateral plate mesoderm
cells to commit towards endothelial lineage. Differenti-
ation was performed using BMP4 and VEGF after initial
treatment with CHIR99021 and bFGF as illustrated in
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Fig. 2a. The kinetics of differentiation towards endothe-
lial lineage was monitored using VEGFR2 (an early
marker for lateral plate mesoderm-derived progenitors),
CD34 (early marker for progenitors with potential to dif-
ferentiate towards hemato-endothelial lineage), CD31
(pan-endothelial lineage marker) and platelet-derived
growth factor (PDGF)Rβ (early marker for paraxial
mesoderm). Real-time PCR analysis (Fig. 2b) revealed
BMP4 supplementation resulted in upregulation of
VEGFR2, but had minimal effect on the expression levels
of CD34 and CD31. On the contrary, treatment with
VEGF resulted in a modest increase in the transcript
levels of CD34, CD31 and VEGFR2 and downregulation
of PDGFRβ, while combined modulation with BMP4
and VEGF resulted in marked upregulation of CD34,
CD31 and VEGFR2 and marked downregulation of
PDGFRβ. Furthermore, the pluripotency markers were
markedly downregulated under all the three differenti-
ation conditions (Fig. 2c). In accordance with the real-
time PCR data, time-course flow cytometry analysis
(Fig. 3) revealed the gradual emergence of a VEGFR2+
population with BMP4 supplementation, but only a
small subset of this population co-express CD34 (~6.5 %
on day 5), while the addition of VEGF resulted in the
gradual appearance of CD34+ cells that co-express
VEGFR2 and CD31 and account for ~54 % of the differ-
entiated cells by the fifth day of differentiation. Further-
more, combined treatment with BMP4 and VEGF
resulted in a robust emergence of CD34+VEGFR2+/
CD34+CD31+ cells which accounted for ~95 % of the
differentiated cells by the fifth day of differentiation. In
all three differentiation conditions, time-course flow cy-
tometry plots also reveal the temporal emergence of a
VEGFR2+ population that gradually attains CD34 and
CD31 positivity. These findings suggest the role of VEGF
in induction to lateral plate mesodermal progenitors
(VEGFR2+ cells) and further to endothelial progenitors
(CD34+CD31+VEGFR2+ cells) and a synergistic role of
BMP4 resulting in robust commitment to the endothe-
lial lineage. We verified the robustness of the protocol
using H9-hESCs which also yielded ~90 % of cells positive
for VEGFR2, CD34 and CD31 (Additional file 1: Figure
S5). In conclusion, step-wise treatment of hESCs with
GSK-3 inhibitor, bFGF followed by BMP4 and VEGF re-
sults in sequential emergence of Brachyury+ PS , VEGFR2+
early mesoderm/lateral mesoderm cells followed by robust
commitment to endothelial lineage yielding ~90–95 %
of CD34+CD31+(VEGFR2+) endothelial progenitor cells
Fig. 3 Flow cytometry analysis of induction of H1-hESCs towards endothelial lineage. Representative flow cytometry overlays display the kinetics
of co-expression of vascular endothelial growth factor receptor-2 (VEGFR2) and CD34 (a), and CD31 and CD34 (b) upon induction of H1-hESCs
with BMP4 (Gi.F.B), VEGF (Gi.F.V) and BMP4 + VEGF (Gi.F.BV) over a differentiation period of 5 days
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within a differentiation span of 5 days under feeder-free,
and chemically defined conditions.
Terminal differentiation of CD34+CD31+ endothelial
progenitors to arterial and venous endothelial cells under
serum-free conditions
Under serum-containing conditions, high concentrations
(50 ng/ml) of VEGF have been reported to aid arterial
differentiation, while lower concentrations (10 ng/ml)
aid venous commitment of mouse ESCs and human
iPSCs [27–29]. However, differentiation of hESCs to ar-
terial and venous ECs and, specifically, differentiation
under serum-free conditions has not been reported so
far. The CD34+CD31+ endothelial progenitors were
sorted and further differentiated towards endothelial
subtypes in serum-free conditions using commercially
available ESFM. Serum-containing endothelial medium
typically requires supplementation with FBS (2–5 %), in-
sulin, heparin, ascorbic acid, hydrocortisone, insulin-like
growth factor, bFGF, EGF and VEGF, but the serum-free
endothelial medium as per manufacturer’s instructions
requires supplementation with bFGF (20 ng/ml) and
EGF (10 ng/ml) only. Hence we initially carried out the
differentiation of the CD34+CD31+ cells in ESFM sup-
plemented with bFGF and EGF for 3–6 passages (Fig. 4a).
Differentiation under these conditions yielded 98–99 %
CD34+/CD31+/VE-CAD+ ECs (Fig. 4b). Real time RT-
PCR analysis demonstrated upregulation of all transcripts
associated with endothelial lineage (Fig. 5a). Additionally,
immunocytochemistry revealed the expression of CD31,
VE-CAD and vWF (Fig. 5b). Further analysis into the
arterial and venous phenotype markers showed almost
80–90 % of the cells to be positive for venous markers
(NRP2, EPH-B4) while only ~2–10 % of the cells differen-
tiated from H1/H9-hESCs expressed NRP1 and DLL4,
and ~13–17 % expressed CXCR4 (Fig. 4b). The endothe-
lial, arterial and venous marker expression profiles were
similar to those expressed by human umbilical vein endo-
thelial cells (HUVECs) (Figs. 4 and 5).These observations
suggest the commitment of CD34+CD31+ cells towards
venous endothelial phenotype and these would be referred
to as hESC-Ven-ECs (H1/H9).
VEGF has been reported as critical for vascular pat-
terning governing the specification towards arterial
phenotype through a cascade of signaling events involv-
ing Shh, Notch, Dll4 and Ephrin-B2 [3, 30–32]. Similar
studies on mouse ESCs [29, 30], human adult progeni-
tors [33] and human iPSCs [28] have shown high con-
centrations of VEGF favoring arterial specification. To
ascertain if the CD34+CD31+ cells had the potential to
commit towards arterial phenotype, we additionally sup-
plemented the ESFM with VEGF in addition to EGF and
bFGF. Surprisingly, when the CD34+CD31+ cells were
exposed to high concentrations of VEGF (50 ng/ml), we
observed apoptosis of the cells. Titration of VEGF con-
centration and analysis of apoptotic cell death using
AnnexinV-Propidium iodide staining revealed the occur-
rence of cellular apoptosis in a dose-dependent manner
with the optimal concentration around 5–10 ng/ml
VEGF (Additional file 1: Figure S6). Differentiation of
H1/H9-hESC-derived CD34+CD31+ cells in the presence
of 10 ng/ml VEGF for 3–6 passages, yielded almost 95–
99 % of CD34+/CD31+/VE-CAD+ ECs (Fig. 4b). Flow cy-
tometry analysis showed that these ECs were also posi-
tive for arterial markers (NRP1, DLL4, CXCR4) and only
5–6 % of the cells were positive for venous markers
(NRP2, EPH-B4) (Fig. 4b). When compared to Ven-ECs,
H1/H9-hESC-derived endothelial progenitors differenti-
ated under the influence of VEGF displayed significantly
higher levels of CD31, vWF, eNOS and Tie2 (Fig. 5a).
Real-time PCR analysis also revealed that these cells had
significantly higher levels of arterial markers and lower
levels of venous endothelial markers (Fig. 5a). The endo-
thelial, arterial and venous marker expression profiles
were similar to those expressed by human coronary ar-
tery endothelial cells (HCAECs) (Figs. 4 and 5). The ex-
pression profile of the cells differentiated under the
influence of low concentrations of VEGF indicate the
commitment of CD34+CD31+ cells towards arterial
endothelial phenotype and these would be referred to as
hESC-Art-ECs (H1/H9). Furthermore, both hESC-Art-
ECs and hESC-Ven-ECs were functional in terms of
their ability for acetylated low-density lipoprotein uptake
and formation of cord-like structures over Matrigel
(Fig. 5b).
Studies have shown that ECs commit to arterial or
venous fate in early embryonic development. However,
studies suggest that ECs display a certain degree of plas-
ticity and express characteristics of alternative endothe-
lial phenotypes [34–36]. This degree of plasticity of
endothelial phenotypes is poorly understood, though
studies suggest the role of hemodynamic forces, micro-
environment, smooth muscle coverage, wounding and
pathological conditions [34–38]. Hence, to examine
whether these hESC-derived ECs are committed to an
arterial or venous fate, we cross-cultured the hESC-
derived arterial ECs in venous media conditions (i.e., in
the absence of VEGF) and hESC-derived venous ECs in
arterial media conditions by supplementing the medium
with VEGF. Both H1- and H9-hESC-derived arterial
ECs, upon culture under venous conditions for two pas-
sages, resulted in a 15–25 % reduction in the number of
ECs expressing arterial markers (NRP1 and DLL4) and
were associated with a 12–20 % increase in the number
of ECs expressing venous markers (NRP2 and EPH-B4)
(Additional file 1: Figure S7). Similarly, culture of H1- and
H9-hESC-derived venous ECs under arterial conditions
for two passages resulted in a 15–20 % reduction in the
Sriram et al. Stem Cell Research & Therapy  (2015) 6:261 Page 7 of 17
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number of ECs expressing venous markers and was asso-
ciated with a 7–15 % increase in the number of ECs ex-
pressing arterial markers. Hence, the changes in culture
conditions resulted in transition of a small subset of the
arterial ECs to venous phenotype and vice versa.
In summary, we developed a protocol that results in rapid
and efficient differentiation of hESCs to CD34+CD31+
endothelial progenitors with the potential to commit
to arterial and venous endothelial phenotypes under
feeder- and serum-free conditions through modulating
the concentration of VEGF.
Intrinsic differences in cell migration and angiocrine
secretome profiles of hESC-derived arterial and venous
ECs
ECs interact with the local microenvironment and sup-
port tissue regeneration after injury through revascula-
rization of the newly healed tissue and expression of
various trophic growth factors, known as angiocrine fac-
tors, which lead to proliferation and migration of ECs
from pre-existing blood vessels. To assess cell migration,
in vitro wound closing assays were performed over a
period of 24 hours. Compared to H1-Ven-ECs, the H1-
Art-ECs displayed faster closure of the wound area
resulting in a complete wound closure by H1-Art-ECs in
~15 hours in contrast to ~27 hours taken by H1-Ven-
ECs (Fig. 6a). Similarly, the H9-Art-ECs and HCAECs
displayed faster closure of the scratch wound compared
to respective venous phenotypes (Fig. 6a). ECs pertaining
to distinct vascular beds have recently been reported to
display significant differences in expression profiles of
various transcriptomes, angiocrine factors and surface
markers [39]. However, the distinct expression of various
angiocrine factors by different endothelial phenotypes of
hESC origin still needs to be explored. To probe into the
profile of various angiocrine factors secreted by hESC-
derived ECs, we used angiogenesis antibody array of 55
different proteins related to angiogenesis, growth factors
and related proteins, cytokines, proteases and their inhibi-
tors, neurotrophic factors, and anti-angiogenic factors.
Both H1-Art-ECs and H1-Ven-ECs displayed marked
induction of endothelin-1, insulin-like growth factor-
binding protein-2 (IGFBP-2), monocyte chemoattractant
protein-1 (MCP-1), pentraxin-3, serpin-E1 and tissue in-
hibitor of matrix metalloproteinase-1 (TIMP-1) (Fig. 6;
Additional file 1: Figure S7 and Table S1). However, the
conditioned media of H1-Ven-ECs had significantly higher
levels of Activin-A, IGFBP-3, and interleukin-1β com-
pared to H1-Art-ECs (Fig. 6c). On the contrary, the media
conditioned by H1-Art-ECs had significantly higher levels
of IGFBP-1, interleukin-8, matrix metalloproteinase-9
(MMP-9), PDGF-AA and thrombospondin-1 (TSP-1)
compared to that of H1-Ven-ECs (Fig. 6c). These results
emphasize the existence of intrinsic differences between
arterial and venous endothelial phenotypes. However, fur-
ther studies on the differences in secretome profiles
among the two endothelial phenotypes and their in vivo
relevance are needed to understand the role of endothelial
heterogeneity.
Transplantation of hESC-derived arterial and venous ECs
result in formation of microvessels
After assessment of the in vitro functionality of the
hESC-derived arterial and venous ECs, we investigated
whether these ECs have the ability to form functional
microvessels upon transplantation, by injecting ECs sus-
pended in Matrigel subcutaneously into the dorsal re-
gion of immunodeficient mice. Matrigel plugs implanted
without cells exhibited no evidence of microvessels
within the matrix (Fig. 7a). On the other hand, the
Matrigel plugs implanted along with hESC-Art-ECs or
hESC-Ven-ECs showed the presence of microvessels
within the matrix. Additionally, these microvessels were
seen to be connected to the host circulation, as evi-
denced by the presence of red blood cells within the
lumen (Fig. 7a). Furthermore, these microvessels were
reactive for anti-human CD31 and anti-human collagen-
IV, indicating that they were of human origin (Fig. 7b).
Furthermore, the hESC-Art-ECs and hESC-Ven-ECs
largely maintained their respective phenotypes in vivo,
as evidenced by the expression of Ephrin-B2 and Eph-B4,
respectively (Fig. 7b). However, few microvessels formed
by hESC-Art-ECs showed the expression of venous
markers and vice versa.
To determine if the hESC-derived arterial and venous
ECs have tumorogenic potential, we transplanted H1-
hESC-derived arterial and venous ECs and their cell
source (H1-hESCs) into immunocompromised mice. All
the mice injected with H1-hESCs developed teratomas
within 3–4 months of transplantation, while none of
(See figure on previous page.)
Fig. 4 Flow cytometry characterization of terminal differentiation of CD34+CD31+ endothelial progenitors to venous and arterial endothelial cells
under serum-free conditions. a Schematic representation of differentiation of hESCs to endothelial progenitors and further differentiation towards
venous ECs (hESC-Ven-ECs) and arterial ECs (hESC-Art-ECs). b Representative flow cytometry histogram overlays represent the expression of
pan-endothelial, arterial and venous markers among H1-Ven-ECs, H1-Art-ECs, H9-Ven-ECs, H9-Art-ECs, HUVECs, and HCAECs. bFGF Basic fibroblast
growth factor, BMP4 Bone morphogenetic protein 4, EGF Epidermal growth factor, GSKi Glycogen synthase kinase inhibitor (CHIR99021), HCAEC
Human coronary artery endothelial cells, hESC Human embryonic stem cells, HUVEC Human umbilical vein endothelial cells, VEGF Vascular
endothelial growth factor
Sriram et al. Stem Cell Research & Therapy  (2015) 6:261 Page 9 of 17
Fig. 5 (See legend on next page.)
Sriram et al. Stem Cell Research & Therapy  (2015) 6:261 Page 10 of 17
Fig. 6 Assessment of cell migration and survey of angiocrine secretome profiles of hESC-derived arterial and venous ECs. a Graphical representation of
kinetics of wound coverage among H1-Ven-ECs and H1-Art-ECs (left panel), H9-Ven-ECs and H9-Art-ECs (middle panel), HUVECs, and HCAECs (right panel).
Error bars show standard deviation; n = 3. *p < 0.05, **p < 0.01. b Representative scans of angiogenesis antibody arrays demonstrating the secretion of
various angiocrine factors by H1-Ven-ECs and H1-Art-ECs. Array images are obtained from 10-minute exposure of X-ray film. (Refer to Additional file 1 for
co-ordinates of the antibody array). c Graphical representation of the relative amounts of selected angiocrine factors that show significant differences
among the H1-hESC derived arterial and venous ECs. The bars represent relative amounts of factors secreted based on densitometric analysis of relative
pixel density of the blots. Error bars show the standard deviation of two independent experiments. *p < 0.05, **p < 0.01. Art-EC Arterial endothelial cells,
HCAEC Human coronary artery endothelial cells, hESC Human embryonic stem cells, HUVEC Human umbilical vein endothelial cells, IGF Insulin-like growth
factor, IL Interleukin, MCP monocyte chemoattractant protein, MMP Matrix metalloproteinase, PDGF Platelet-derived growth factor, TIMP Tissue inhibitor
of matrix metalloproteinase, Ven-EC Venous endothelial cells
(See figure on previous page.)
Fig. 5 Characterization of hESC-derived venous and arterial endothelial cells. a Profiles of transcripts related to endothelial, arterial and venous
phenotypes among Ven-ECs and Art-ECs derived from H1-hESCs, H9-hESCs and primary cells (PC: HUVECs and HCAECs). Gene expression levels
were normalized to corresponding β-ACTIN values and are represented as relative to undifferentiated hESCs. b Representative photomicrographs
of H1-Ven-ECs, H1-Art-ECs, H9-Ven-ECs, H9-Art-ECs, HUVECs, and HCAECs show the cobblestone morphology of ECs under phase contrast microscopy,
and immunofluorescence images demonstrate the expression of pan-endothelial markers CD31, VE-Cadherin, and von Willebrand factor (vWF), uptake
of Dil-acetylated low-density lipoprotein (Dil-Ac-LDL) and formation of cord-like structures over Matrigel (Green-CalceinAM). Scale bars = 150 μm. Error
bars show standard deviation; n≥ 3. *p < 0.05, **p < 0.01. Art-EC Arterial endothelial cells, HCAEC Human coronary artery endothelial cells, hESC Human
embryonic stem cells, HUVEC Human umbilical vein endothelial cells, Ven-EC Venous endothelial cells
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Fig. 7 In vivo safety and functionality assessment of hESC-derived arterial and venous endothelial cells. a Representative hematoxylin and eosin
(H&E) stained micrographs of Matrigel plug study showing absence of microvessels in Matrigel-only control, while the others show the formation
of perfused microvessels by engrafted hESC-derived arterial and venous ECs. b Histochemical micrographs of microvessels formed by hESC-derived
arterial and venous ECs stained for hCD31, hCollagen-IV, hEphrin-B2 and hEph-B4. c Representative photographs showing the presence or
absence of teratoma formation in immunodeficient mice. d Representative H&E stained micrographs showing the formation of teratoma by
H1-hESCs with evidence of differentiation to derivatives of three germ layers: ectoderm (hair follicles, <), mesoderm (cartilage, *), and endoderm
(glandular structures, +). e Representative H&E stained micrographs showing the absence of teratoma formation by H1-hESCs derived arterial
and venous ECs. Scale bars in (a) and (b) = 100 μm; in (d) and (e) = 500 μm. Art-EC Arterial endothelial cells, hESC Human embryonic stem cells,
Ven-EC Venous endothelial cells
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those that received either of the ECs showed sign of
teratoma for the same period of time (Fig. 7c-e). Hence,
the hESC-derived arterial and venous ECs differentiated
under feeder- and serum-free conditions were functional
and non-tumorogenic in-vivo.
Discussion
In the present study, we demonstrate a novel and effi-
cient protocol for monolayer differentiation of hESCs to-
wards arterial and venous ECs under feeder- and serum-
free conditions. These hESC-derived arterial and venous
ECs demonstrate differences in gene expression and
angiocrine secretion profiles, and form functional micro-
vessels in vivo. Despite tremendous progress in the dif-
ferentiation of hESCs to ECs, current protocols are
inefficient predominantly due to a poorly controlled dif-
ferentiation microenvironment and lack of the concept
of a lineage-directed approach [5]. We [17] and others
[23, 24, 40–43] have demonstrated that activation of the
Wnt/β-Catenin pathway with or without BMP4 and
Activin-A efficiently drives the differentiation of PSCs
towards mesoderm and endoderm lineages. Cao et al.
demonstrated the robust differentiation of PSCs to car-
diovascular progenitors upon combined treatment with
BMP4, CHIR99021 and ascorbic acid in a chemically de-
fined medium under feeder- and serum-free culture con-
ditions [44]. Similarly, a recent report demonstrates a
robust commitment of human iPSCs towards mesoderm
in the presence of the GSK-3 inhibitor CHIR99021
followed by induction to cardiac progenitors upon β-
Catenin siRNA knockdown, suggesting a dual function
of the Wnt/β-Catenin pathway during early cardiovascu-
lar development [45]. In this study, we directed the
hESCs towards lateral plate mesoderm under feeder-free
and chemically defined conditions through short-term
inhibition of GSK-3 followed by treatment with bFGF
and BMP4. Currently available protocols to differentiate
hESC and hiPSCs towards endothelial lineage generally
requires 10–15 days of differentiation to achieve a mod-
est 2–40 % of progenitor cells committed to endothelial
lineage [5]. Recent reports show commitment of hESCs
to endothelial lineage with ~50 % efficiency by using
GSK-3 inhibition and treatment with BMP4 at early
stages of differentiation, followed by treatment with
BMP4 and inhibition of Notch/TGFβ signaling pathways
[17, 40]. Though a detailed comparison with published
protocols was not undertaken, our current findings sug-
gest a robust commitment (90–95 %) towards endothe-
lial lineage within a differentiation span of 5 days.
Furthermore, the differentiation protocol primarily re-
sults in generation of CD34+CD31+ cells, in comparison
to previously published methods which generates a mix-
ture of CD34+CD31−, CD34−CD31+ CD34+CD31+ and
CD34−CD31− cells [46, 47]. The robustness of our
endothelial differentiation protocol was verified among
two different hESC lines; however, it needs further valid-
ation using other hESC lines and iPSCs.
Distinction of arterial and venous endothelial pheno-
types seems to occur quite early in the development
even before the onset of circulation, wherein VEGF, Shh,
and Notch signaling have been suggested to play a crucial
role [31, 32]. In vitro studies using mouse PSCs [29, 48]
indicate the expression of arterial markers such as Dll4,
EphrinB2 and Notch4 in response to high concentrations
of VEGF (50 ng/ml), while lower concentrations (10 ng/
ml) resulted in upregulation of the venous marker COUP-
TFII. Additionally, the VEGF-mediated arterialization was
reported to be further enhanced by the addition of adre-
nomedullin [27, 48] and these effects were blocked in the
absence of Notch signaling [27, 29]. These findings from
in vitro models correlate with the findings of in vivo ani-
mal models highlighting the coordinated activation of
VEGF-Notch signaling in arterial specification. Though
tremendous amounts of information have been obtained
from in vitro human models, the heterogeneity of ECs
and/or derivation of tissue-specific ECs have been investi-
gated by very few studies. Human cord blood-derived
endothelial progenitors [49] and hPSCs [50, 51] upon co-
culture with neural cells differentiate to brain-specific ECs
and express markers and functions related to the blood–
brain barrier. Recent studies based on plastic conversion
of fibroblasts to ECs and iPSC-derived ECs reported the
pool of terminally differentiated ECs as being heteroge-
neous in terms of expression of arterial, venous and
lymphatic markers [52, 53]. However, distinct specification
towards either phenotype is not investigated. Only two
studies using human adult progenitors [33] and human
iPSCs [28] have elucidated the arterial–venous specification
of human progenitor/stem cells to date. Aranguren et al.
reported that a high concentration of VEGF (100 ng/ml)
induced arterial differentiation of human bone marrow-
derived multipotent adult progenitor cells [33]. Further-
more, the arterial induction was reported to be enhanced
by supplementation with Dll4 and Shh, while blockade of
Notch and/or Shh led to attenuation of arterial differenti-
ation and upregulation of venous markers. Similarly,
Rufaihah et al., using human iPSCs, demonstrated arterial
differentiation by high VEGF concentration coupled with
cAMP, and induction of venous specification under low
concentrations of VEGF [28]. In summary, all the above
studies in mouse and human in vitro models indicate the
dose-dependent effect of VEGF in arterial–venous specifi-
cation of ECs; however, these studies were performed
under serum-containing conditions.
Inclusion of xenogeneic products (like Matrigel, FBS,
murine stromal cells) in the culture milieu could influ-
ence the differentiation outcome and limit the ability to
tune the microenvironment due to the presence of
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unknown/poorly defined factors [16]. To eliminate or re-
duce the use of xenogeneic products, we have developed
a novel feeder- and serum-free protocol for differenti-
ation of hESCs to endothelial subtypes. Under serum-
free conditions, we found higher concentrations of
VEGF (25–100 ng/ml) caused apoptosis of the cells,
while at lower concentrations (10 ng/ml) it directs to-
wards the arterial phenotype and in its absence favors
the venous fate. Spatially different response of hESC-
derived endothelial progenitors to various concentra-
tions of VEGF is in contrast to the findings previously
reported under serum-containing conditions which
could be due the presence of serum in the culture mi-
lieu. These novel insights into the arterial–venous spe-
cification under serum-free conditions could provide
clues for developing clinically competent vascular cells
in the future. However, in the current methodology,
the hESCs cultured in mTeSR1 over Matrigel were
used. Matrigel is of murine origin and mTeSR1 con-
tains certain components of xenogeneic origin. Sec-
ondly, both H1 and H9 hESCs used in the current
study were originally derived under xenogeneic condi-
tions. Matrigel-based feeder-free culture systems have
been successfully replaced with the use of xeno-free
matrices and culture media [54–59]. Hence, future
studies using hESCs and iPSCs derived and cultured
under xeno-free conditions are warranted for deriv-
ation of clinically competent ECs.
From a drug discovery and clinical therapeutic stand-
point, we reduced the use of xenogeneic products and
further demonstrated the safety and the ability of hESC-
derived arterial and venous ECs to form microvessels
upon transplantation in a mouse model. Microvessels
derived from arterial and venous endothelial phenotypes
were functionally integrated with the host vasculature.
Furthermore, the hESC-derived arterial and venous ECs
maintained the expression of the arterial marker
(Ephrin-B2) and venous marker (Eph-B4), respectively.
However, a few microvessels formed by arterial ECs
expressed the venous marker and vice versa, which
might indicate either the ECs were not sufficiently pure
enough or they underwent a phenotypic change in
vivo—both possibilities are equally plausible. Flow cy-
tometry analysis of the arterial and venous markers
among the ECs show that a small proportion of venous
ECs express arterial markers de novo, and the propor-
tion of these venous ECs expressing arterial markers in-
creases upon culture under arterial conditions (and vice
versa). From a phenotypic stability standpoint, ECs (es-
pecially arterial ECs) require the support of mural cells
Fig. 8 Schematic diagram summarizing the protocol for differentiation of hESCs to endothelial phenotypes. Schematic representation depicts the
differentiation of hESCs to endothelial progenitors and further towards venous and arterial endothelial phenotypes that upon transplantation
form functional microvessels in vivo. bFGF Basic fibroblast growth factor, BMP4 Bone morphogenetic protein 4, EC Endothelial cells, EGF Epidermal
growth factor, hESC Human embryonic stem cells, VEGF Vascular endothelial growth factor
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such as pericytes and vascular smooth muscle cells [3].
In the present study, only ECs (arterial or venous) were
transplanted and were harvested after 2 weeks; thus, in-
vestigating the effect of absence or inclusion of support-
ing mural cells on the phenotypic stability/modulation
would be interesting. Also, the phenotypic stability/
modulation of these microvessels after long-term inte-
gration in the in vivo milieu would be of interest to
understand the arterial–venous specification and modu-
lation. Furthermore, it needs to be determined whether
the enrichment of arterial or venous subtypes favors
therapeutic benefit over a mixed population of ECs. It
might also be plausible that both cells types have specific
indications depending on the therapeutic site or diseased
state as it is well known that endothelial phenotypes
contribute to site-specific predisposition and/or occur-
rence of vascular diseases including atherosclerosis, vas-
cular calcifications, thrombosis and aneurysms.
Furthermore, the role of these endothelial subtypes in
tissue engineering of vascular stents (specifically arterial
or venous stents) would be exciting. These investigations
would be interesting and warranted, but are beyond the
scope of this study.
Conclusion
In conclusion, we demonstrate the efficient differenti-
ation of hESCs to CD34+CD31+ endothelial progenitors
under feeder-free and chemically defined microenvir-
onment by recapitulating the early embryonic vasculo-
genesis through the sequential intervention of GSK-3,
bFGF, BMP4 and VEGF signaling pathways that results
in successive emergence of PS, early mesoderm/lateral
plate mesoderm, and endothelial progenitors (Fig. 8).
Under feeder- and serum-free conditions, these hESC-
derived endothelial progenitors could be directed to arter-
ial and venous ECs depending on the presence or absence
of VEGF. Furthermore, these hESC-derived arterial and
venous ECs demonstrate differences at the transcriptome
and secretome levels, and form functional microvessels
that integrate with the host circulation and maintain their
respective phenotypes in vivo. The efficient generation of
these hESC-derived endothelial progenitors and endothe-
lial phenotypes may be more amenable for large-scale pro-
duction and expansion. Furthermore, we believe that the
findings of our study could be translated using other
hESCs and iPSCs for developing personalized cell therapy,
drug discovery and disease-modeling applications. Fur-
thermore, the access to robust differentiation of human
PSCs to arterial and venous ECs under defined conditions
could provide a potential human model to study arterial–
venous specification for various basic and pharmaceutical
research applications and in the future towards clinical re-
generative therapies.
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